These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 9396640)

  • 1. Issues of cost-effectiveness in the use of antithrombotic therapy for ischemic heart disease.
    Califf RM; Mark DB
    Am Heart J; 1997 Nov; 134(5 Pt 2):S88-96. PubMed ID: 9396640
    [No Abstract]   [Full Text] [Related]  

  • 2. A cost-effectiveness analysis of aspirin versus oral anticoagulants after acute myocardial infarction in Italy -- equivalence of costs as a possible case for oral anticoagulants.
    Gianetti J; Gensini G; De Caterina R
    Thromb Haemost; 1998 Dec; 80(6):887-93. PubMed ID: 9869155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Out of hospital antithrombotic prophylaxis after total hip replacement: low-molecular-weight heparin, warfarin, aspirin or nothing? A cost-effectiveness analysis.
    Sarasin FP; Bounameaux H
    Thromb Haemost; 2002 Apr; 87(4):586-92. PubMed ID: 12008939
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clopidogrel versus aspirin for secondary prophylaxis of vascular events: a cost-effectiveness analysis.
    Schleinitz MD; Weiss JP; Owens DK
    Am J Med; 2004 Jun; 116(12):797-806. PubMed ID: 15178495
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tissue plasminogen activator was cost-effective compared to streptokinase in only selected patients with acute myocardial infarction.
    Kent DM; Vijan S; Hayward RA; Griffith JL; Beshansky JR; Selker HP
    J Clin Epidemiol; 2004 Aug; 57(8):843-52. PubMed ID: 15485737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ischemic heart disease (coronary thrombolysis).
    Kanmatsuse K; Nagao K; Kikushima K; Shioiri K
    Intern Med; 1998 Feb; 37(2):203-5. PubMed ID: 9550610
    [No Abstract]   [Full Text] [Related]  

  • 7. [Antithrombotic therapy in acute coronary syndrome].
    Chazov EI; Panchenko EP
    Ter Arkh; 2000; 72(3):65-75. PubMed ID: 10776658
    [No Abstract]   [Full Text] [Related]  

  • 8. Cost effectiveness of enoxaparin in acute ST-segment elevation myocardial infarction: the ExTRACT-TIMI 25 (Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction 25) study.
    Marcoff L; Zhang Z; Zhang W; Ewen E; Jurkovitz C; Leguet P; Kolm P; Weintraub WS
    J Am Coll Cardiol; 2009 Sep; 54(14):1271-9. PubMed ID: 19778669
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Critical concepts in cost-effectiveness for cardiovascular specialists.
    Califf RM; Eisenstein EL
    Am Heart J; 2000 Dec; 140(6 Suppl):S143-7. PubMed ID: 11100008
    [No Abstract]   [Full Text] [Related]  

  • 10. Easing the economic burden of acute coronary syndromes: cost-effectiveness of emerging therapies.
    Nutescu EA
    Am J Manag Care; 2006 Dec; 12(16 Suppl):S444-50. PubMed ID: 17203989
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Antithrombotic treatment following acute ischemic heart disease: acetylsalicylic acid and (or) oral anticoagulants?; ASPECT-II, a new study].
    van Es RF; Grobbee DE; Deckers JW; Bak AA; Verheugt FW; Jonker JJ
    Ned Tijdschr Geneeskd; 1997 Nov; 141(44):2129-31. PubMed ID: 9550777
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current status of activation markers in ischemic heart disease: markers of coagulation activation.
    Merlini PA; Ardissino D
    Thromb Haemost; 1997 Jul; 78(1):276-9. PubMed ID: 9198166
    [No Abstract]   [Full Text] [Related]  

  • 13. CLINICAL AND PHARMACEUTICAL ASPECTS OF THE USE OF ANTITHROMBOTIC DRUGS IN PATIENTS SUFFERING FROM ISCHEMIC HEART DISEASE (REVIEW).
    Zhunussov Y
    Georgian Med News; 2016 Feb; (251):32-9. PubMed ID: 27001783
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Frequency and costs of ischemic and bleeding complications after percutaneous coronary interventions: rationale for new antithrombotic agents.
    Moscucci M
    J Invasive Cardiol; 2002 Apr; 14 Suppl B():55B-64B. PubMed ID: 11967391
    [No Abstract]   [Full Text] [Related]  

  • 15. Making decisions about antithrombotic therapy in heart disease. Decision analytic and cost-effectiveness issues.
    Eckman MH; Levine HJ; Pauker SG
    Chest; 1995 Oct; 108(4 Suppl):457S-470S. PubMed ID: 7555196
    [No Abstract]   [Full Text] [Related]  

  • 16. Stratified cost-effectiveness analysis: a framework for establishing efficient limited use criteria.
    Coyle D; Buxton MJ; O'Brien BJ
    Health Econ; 2003 May; 12(5):421-7. PubMed ID: 12720259
    [TBL] [Abstract][Full Text] [Related]  

  • 17. What is the optimal medical management of ischemic heart failure?
    Cleland JG; Alamgir F; Nikitin NP; Clark AL; Norell M
    Prog Cardiovasc Dis; 2001; 43(5):433-55. PubMed ID: 11251129
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel antithrombotic regimen in patients with ischemic heart disease and peripheral arterial disease: can we identify those who derive the highest benefit?
    Mahtta D; Virani SS
    J Med Econ; 2020 Jul; 23(7):670-672. PubMed ID: 32267794
    [No Abstract]   [Full Text] [Related]  

  • 19. Potential cost effectiveness of tissue plasminogen activator among patients previously treated with streptokinase.
    Massel D
    Can J Cardiol; 1999 Feb; 15(2):173-9. PubMed ID: 10079776
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antithrombotic therapy in heart failure: WATCHful wondering.
    Konstam MA
    Circulation; 2009 Mar; 119(12):1559-61. PubMed ID: 19332479
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.